JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $179

Benzinga Newsdesk www.benzinga.com Negative 91.1%

Neg 91.1% Neu 0% Pos 0%

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $180 to $179.